GlassScriptPhysician profile
Evan D Stathulis
NPI 1215904180
$12,998.45
in general payments reported to CMS, 2019-2025
67 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $1,488 · 2021: $1,933 · 2022: $2,059 · 2023: $1,813 · 2024: $1,839 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,791.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,809.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,453.25 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,181.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $861.15 | 2019-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $752.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $721.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.61 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Glaxosmithkline, LLC. | $594.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $469.42 | 2019-2022 | |
| Amgen INC. | $373.86 | 2019-2025 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $309.42 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.19 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $243.67 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $227.16 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $215.76 | 2021-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Stathulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.